Anna Malczewska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7334561/publications.pdf

Version: 2024-02-01

471509 526287 34 766 17 27 citations h-index g-index papers 34 34 34 787 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Circulating MicroRNAs in Small-bowel Neuroendocrine Tumors. Annals of Surgery, 2021, 274, e1-e9.	4.2	20
2	Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience. Neuroendocrinology, 2021, 111, 304-319.	2.5	18
3	NETest is superior to chromogranin A in neuroendocrine neoplasia: a prospective ENETS CoE analysis. Endocrine Connections, 2021, 10, 110-123.	1.9	17
4	Early Identification of Residual Disease After Neuroendocrine Tumor Resection Using a Liquid Biopsy Multigenomic mRNA Signature (NETest). Annals of Surgical Oncology, 2021, 28, 7506-7517.	1.5	25
5	Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. Annals of Surgery, 2021, 274, 481-490.	4.2	22
6	Circulating biomarkers of gastroenteropancreatic and lung neuroendocrine neoplasms: "The times they are a changin― Current Opinion in Endocrine and Metabolic Research, 2021, 18, 243-253.	1.4	4
7	An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis. Neuroendocrinology, 2020, 110, 198-216.	2.5	28
8	Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms. Neuroendocrinology, 2020, 110, 185-197.	2.5	14
9	The clinical applications of a multigene liquid biopsy (NETest) in neuroendocrine tumors. Advances in Medical Sciences, 2020, 65, 18-29.	2.1	38
10	PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 895-906.	6.4	73
11	The NETest liquid biopsy is diagnostic for gastric neuroendocrine tumors: observations on the blood-based identification of microscopic and macroscopic residual disease. BMC Gastroenterology, 2020, 20, 235.	2.0	8
12	Molecular identification of bronchopulmonary neuroendocrine tumours and neuroendocrine genotype in lung neoplasia using the NETest liquid biopsy. European Journal of Cardio-thoracic Surgery, 2020, 57, 1195-1202.	1.4	6
13	Evaluation of circulating transcript analysis (NETest) in small intestinal neuroendocrine neoplasms after surgical resection. Endocrine, 2020, 69, 430-440.	2.3	7
14	A genomic blood test (NETest) identifies neuroendocrine transformation of prostate cancer Journal of Clinical Oncology, 2020, 38, e17511-e17511.	1.6	0
15	A multi-gene colorectal cancer liquid biopsy with >90% accuracy in diagnosis and assessment of disease status Journal of Clinical Oncology, 2020, 38, e16079-e16079.	1.6	O
16	The utility of blood-based molecular tools-the NETest-to monitor and evaluate the efficacy of PRRT in neuroendocrine tumors Journal of Clinical Oncology, 2020, 38, 3568-3568.	1.6	0
17	A blood-based multi-mRNA liquid biopsy with >90% accuracy for diagnosis and assessment of prostate cancers Journal of Clinical Oncology, 2020, 38, 5574-5574.	1.6	1
18	Inefficacy of chromogranin a assays as neuroendocrine tumor diagnostic tools compared to the NETest Journal of Clinical Oncology, 2020, 38, 4612-4612.	1.6	0

#	Article	IF	CITATIONS
19	PRRT neuroendocrine tumor response assessment using blood transcript analysis: The NETest Journal of Clinical Oncology, 2020, 38, 625-625.	1.6	O
20	ENETS single center of excellence experience with the NETest: A real-world assessment of 565 patients Journal of Clinical Oncology, 2020, 38, 605-605.	1.6	0
21	A 13-gene colorectal cancer liquid biopsy with greater than 90 percent accuracy in diagnosis and assessment of disease status Journal of Clinical Oncology, 2020, 38, 18-18.	1.6	3
22	Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis. PLoS ONE, 2019, 14, e0218592.	2.5	17
23	NETest Liquid Biopsy Is Diagnostic of Lung Neuroendocrine Tumors and Identifies Progressive Disease. Neuroendocrinology, 2019, 108, 219-231.	2.5	27
24	Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus. Journal of Nuclear Medicine, 2019, 60, 7-8.	5.0	10
25	Blood mRNA Measurement (NETest) for Neuroendocrine Tumor Diagnosis of Image-Negative Liver Metastatic Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 867-872.	3 . 6	29
26	NETest liquid biopsy is diagnostic of small intestine and pancreatic neuroendocrine tumors and correlates with imaging. Endocrine Connections, 2019, 8, 442-453.	1.9	27
27	The utility of blood neuroendocrine gene transcript measurement in the diagnosis of bronchopulmonary neuroendocrine tumours and as a tool to evaluate surgical resection and disease progressionâ€. European Journal of Cardio-thoracic Surgery, 2018, 53, 631-639.	1.4	35
28	A Comprehensive Assessment of the Role of miRNAs as Biomarkers in Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology, 2018, 107, 73-90.	2.5	61
29	Surgical Management of Patients with Neuroendocrine Neoplasms of the Appendix: Appendectomy or More. Neuroendocrinology, 2018, 106, 242-251.	2.5	70
30	Measurement of circulating transcript levels (NETest) to detect disease recurrence and improve followâ€up after curative surgical resection of wellâ€differentiated pancreatic neuroendocrine tumors. Journal of Surgical Oncology, 2018, 118, 37-48.	1.7	30
31	The NETest. Endocrinology and Metabolism Clinics of North America, 2018, 47, 485-504.	3.2	91
32	Predicting the survival of patients with small bowel neuroendocrine tumours: comparison of 3 systems. Endocrine Connections, 2017, 6, 71-81.	1.9	25
33	Nutritional status at the moment of diagnosis in childhood cancer patients. Pediatric Endocrinology, Diabetes and Metabolism, 2017, 23, 77-82.	0.7	6
34	MicroRNAs associated with small bowel neuroendocrine tumours and their metastases. Endocrine-Related Cancer, 2016, 23, 711-726.	3.1	54